Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders
Most children with paediatric neurotransmitter diseases have global functional deficits secondary to central nervous system damage. Paediatric physiatrists, working in conjunction with a multi-disciplinary team, help to improve physical function by normalizing muscle tone and improving body position...
Gespeichert in:
| Veröffentlicht in: | Journal of inherited metabolic disease 2009-06, Vol.32 (3), p.381-386 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 386 |
|---|---|
| container_issue | 3 |
| container_start_page | 381 |
| container_title | Journal of inherited metabolic disease |
| container_volume | 32 |
| creator | Evans, S Forester, K Pettiford, J. M Morozova, O |
| description | Most children with paediatric neurotransmitter diseases have global functional deficits secondary to central nervous system damage. Paediatric physiatrists, working in conjunction with a multi-disciplinary team, help to improve physical function by normalizing muscle tone and improving body position. Components of spasticity, rigidity, and dystonia may all need to be considered in a comprehensive treatment programme. Complications of disordered tone include skin breakdown, pain, sleep disturbance, and dysphagia. With an integrated approach to use of medications and equipment as well as implementation of therapy and therapeutic exercise, physiatrists can help maximize functional independence for children with this group of disorders. Pharmacological treatment includes GABA-agonists including baclofen and benzodiazepines, alpha-2 adrenergic agonists, l-dopa and dopaminergic agents, and dantrolene. Intrathecal baclofen may be used in patients refractory to these medications. In addition, physicians may utilize botulinum toxin, phenol, or surgical interventions such as selective dorsal rhizotomy or tendon lengthening. Pharmacological treatment must be used in conjunction with appropriate adaptive equipment in order to maximize therapeutic benefit. Focus on function in an attempt to increase independence is targeted to improve the child's quality of life. We present a framework and rationale to the management of the functional consequences of the paediatric neurotransmitter diseases. |
| doi_str_mv | 10.1007/s10545-009-1190-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67282998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1747905231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4541-3cce57aeb4a8cf3fb4c7c89c55cd3fa2e6665c7b3488ff19a3cdcd9f9c34109d3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EotvCD-ACEVK5BTz-9rEqX4uKOEDPltexd11lncVOqPbf45KIShzoyYd5nvHMvAi9APwWMJbvCmDOeIuxbgE0bvEjtAIuaUuE4I_RCgODVmnOT9BpKTe4gorzp-gENGMahFihcZ1c9rbEtG0Ou2OJzvZNmJIb45CacZeHabubK3bM0TUxjT7_8ulPPQy5cbvYd9mn5jaOlbS-W8jkpzyM2aayj2OVmi6WIXc-l2foSbB98c-X9wxdf_zw4_Jze_Xt0_ry4qp1jNfJqXOeS-s3zCoXaNgwJ53SjnPX0WCJF3VNJzeUKRUCaEtd5zodtKMMsO7oGXoz9z3k4efky2j2sTjf9zb5YSpGSKKI1upBkGAhJJe6gq__AW-GKae6hCGglJCCswrBDLk8lJJ9MIcc9zYfDWBzF5yZgzM1D3MXnMHVebk0njZ7390bS1IVOF8AW2pGod7VxfKXIyBBASaVkzN3G3t_fPhn82X99T2mCqpJZrNUKW19vt_tf3O_mqVgB2O3uY50_Z1goBgEFRwY_Q3wbc1b</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218867654</pqid></control><display><type>article</type><title>Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Access via Wiley Online Library</source><creator>Evans, S ; Forester, K ; Pettiford, J. M ; Morozova, O</creator><creatorcontrib>Evans, S ; Forester, K ; Pettiford, J. M ; Morozova, O</creatorcontrib><description>Most children with paediatric neurotransmitter diseases have global functional deficits secondary to central nervous system damage. Paediatric physiatrists, working in conjunction with a multi-disciplinary team, help to improve physical function by normalizing muscle tone and improving body position. Components of spasticity, rigidity, and dystonia may all need to be considered in a comprehensive treatment programme. Complications of disordered tone include skin breakdown, pain, sleep disturbance, and dysphagia. With an integrated approach to use of medications and equipment as well as implementation of therapy and therapeutic exercise, physiatrists can help maximize functional independence for children with this group of disorders. Pharmacological treatment includes GABA-agonists including baclofen and benzodiazepines, alpha-2 adrenergic agonists, l-dopa and dopaminergic agents, and dantrolene. Intrathecal baclofen may be used in patients refractory to these medications. In addition, physicians may utilize botulinum toxin, phenol, or surgical interventions such as selective dorsal rhizotomy or tendon lengthening. Pharmacological treatment must be used in conjunction with appropriate adaptive equipment in order to maximize therapeutic benefit. Focus on function in an attempt to increase independence is targeted to improve the child's quality of life. We present a framework and rationale to the management of the functional consequences of the paediatric neurotransmitter diseases.</description><identifier>ISSN: 0141-8955</identifier><identifier>EISSN: 1573-2665</identifier><identifier>DOI: 10.1007/s10545-009-1190-0</identifier><identifier>PMID: 19449166</identifier><identifier>CODEN: JIMDDP</identifier><language>eng</language><publisher>Dordrecht: Dordrecht : Springer Netherlands</publisher><subject>Biochemistry ; Biological and medical sciences ; Brain Diseases, Metabolic, Inborn - etiology ; Brain Diseases, Metabolic, Inborn - therapy ; Child ; General aspects ; Human Genetics ; Humans ; Internal Medicine ; Medical genetics ; Medical sciences ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Models, Biological ; Motor Activity - physiology ; Muscle Tonus - physiology ; Neurotransmitter Agents - deficiency ; Neurotransmitter Agents - physiology ; Pediatrics ; Physical and Rehabilitation Medicine - methods ; Posture - physiology ; Symposium on Neurotransmitter Disorders</subject><ispartof>Journal of inherited metabolic disease, 2009-06, Vol.32 (3), p.381-386</ispartof><rights>Springer Science+Business Media B.V. 2009</rights><rights>2009 SSIEM</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4541-3cce57aeb4a8cf3fb4c7c89c55cd3fa2e6665c7b3488ff19a3cdcd9f9c34109d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10545-009-1190-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10545-009-1190-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,1417,23930,23931,25140,27924,27925,41488,42557,45574,45575,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21718102$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19449166$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Evans, S</creatorcontrib><creatorcontrib>Forester, K</creatorcontrib><creatorcontrib>Pettiford, J. M</creatorcontrib><creatorcontrib>Morozova, O</creatorcontrib><title>Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders</title><title>Journal of inherited metabolic disease</title><addtitle>J Inherit Metab Dis</addtitle><addtitle>J Inherit Metab Dis</addtitle><description>Most children with paediatric neurotransmitter diseases have global functional deficits secondary to central nervous system damage. Paediatric physiatrists, working in conjunction with a multi-disciplinary team, help to improve physical function by normalizing muscle tone and improving body position. Components of spasticity, rigidity, and dystonia may all need to be considered in a comprehensive treatment programme. Complications of disordered tone include skin breakdown, pain, sleep disturbance, and dysphagia. With an integrated approach to use of medications and equipment as well as implementation of therapy and therapeutic exercise, physiatrists can help maximize functional independence for children with this group of disorders. Pharmacological treatment includes GABA-agonists including baclofen and benzodiazepines, alpha-2 adrenergic agonists, l-dopa and dopaminergic agents, and dantrolene. Intrathecal baclofen may be used in patients refractory to these medications. In addition, physicians may utilize botulinum toxin, phenol, or surgical interventions such as selective dorsal rhizotomy or tendon lengthening. Pharmacological treatment must be used in conjunction with appropriate adaptive equipment in order to maximize therapeutic benefit. Focus on function in an attempt to increase independence is targeted to improve the child's quality of life. We present a framework and rationale to the management of the functional consequences of the paediatric neurotransmitter diseases.</description><subject>Biochemistry</subject><subject>Biological and medical sciences</subject><subject>Brain Diseases, Metabolic, Inborn - etiology</subject><subject>Brain Diseases, Metabolic, Inborn - therapy</subject><subject>Child</subject><subject>General aspects</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Models, Biological</subject><subject>Motor Activity - physiology</subject><subject>Muscle Tonus - physiology</subject><subject>Neurotransmitter Agents - deficiency</subject><subject>Neurotransmitter Agents - physiology</subject><subject>Pediatrics</subject><subject>Physical and Rehabilitation Medicine - methods</subject><subject>Posture - physiology</subject><subject>Symposium on Neurotransmitter Disorders</subject><issn>0141-8955</issn><issn>1573-2665</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkU1v1DAQhi0EotvCD-ACEVK5BTz-9rEqX4uKOEDPltexd11lncVOqPbf45KIShzoyYd5nvHMvAi9APwWMJbvCmDOeIuxbgE0bvEjtAIuaUuE4I_RCgODVmnOT9BpKTe4gorzp-gENGMahFihcZ1c9rbEtG0Ou2OJzvZNmJIb45CacZeHabubK3bM0TUxjT7_8ulPPQy5cbvYd9mn5jaOlbS-W8jkpzyM2aayj2OVmi6WIXc-l2foSbB98c-X9wxdf_zw4_Jze_Xt0_ry4qp1jNfJqXOeS-s3zCoXaNgwJ53SjnPX0WCJF3VNJzeUKRUCaEtd5zodtKMMsO7oGXoz9z3k4efky2j2sTjf9zb5YSpGSKKI1upBkGAhJJe6gq__AW-GKae6hCGglJCCswrBDLk8lJJ9MIcc9zYfDWBzF5yZgzM1D3MXnMHVebk0njZ7390bS1IVOF8AW2pGod7VxfKXIyBBASaVkzN3G3t_fPhn82X99T2mCqpJZrNUKW19vt_tf3O_mqVgB2O3uY50_Z1goBgEFRwY_Q3wbc1b</recordid><startdate>200906</startdate><enddate>200906</enddate><creator>Evans, S</creator><creator>Forester, K</creator><creator>Pettiford, J. M</creator><creator>Morozova, O</creator><general>Dordrecht : Springer Netherlands</general><general>Springer Netherlands</general><general>Springer</general><general>Blackwell Publishing Ltd</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200906</creationdate><title>Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders</title><author>Evans, S ; Forester, K ; Pettiford, J. M ; Morozova, O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4541-3cce57aeb4a8cf3fb4c7c89c55cd3fa2e6665c7b3488ff19a3cdcd9f9c34109d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biochemistry</topic><topic>Biological and medical sciences</topic><topic>Brain Diseases, Metabolic, Inborn - etiology</topic><topic>Brain Diseases, Metabolic, Inborn - therapy</topic><topic>Child</topic><topic>General aspects</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Models, Biological</topic><topic>Motor Activity - physiology</topic><topic>Muscle Tonus - physiology</topic><topic>Neurotransmitter Agents - deficiency</topic><topic>Neurotransmitter Agents - physiology</topic><topic>Pediatrics</topic><topic>Physical and Rehabilitation Medicine - methods</topic><topic>Posture - physiology</topic><topic>Symposium on Neurotransmitter Disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Evans, S</creatorcontrib><creatorcontrib>Forester, K</creatorcontrib><creatorcontrib>Pettiford, J. M</creatorcontrib><creatorcontrib>Morozova, O</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of inherited metabolic disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Evans, S</au><au>Forester, K</au><au>Pettiford, J. M</au><au>Morozova, O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders</atitle><jtitle>Journal of inherited metabolic disease</jtitle><stitle>J Inherit Metab Dis</stitle><addtitle>J Inherit Metab Dis</addtitle><date>2009-06</date><risdate>2009</risdate><volume>32</volume><issue>3</issue><spage>381</spage><epage>386</epage><pages>381-386</pages><issn>0141-8955</issn><eissn>1573-2665</eissn><coden>JIMDDP</coden><abstract>Most children with paediatric neurotransmitter diseases have global functional deficits secondary to central nervous system damage. Paediatric physiatrists, working in conjunction with a multi-disciplinary team, help to improve physical function by normalizing muscle tone and improving body position. Components of spasticity, rigidity, and dystonia may all need to be considered in a comprehensive treatment programme. Complications of disordered tone include skin breakdown, pain, sleep disturbance, and dysphagia. With an integrated approach to use of medications and equipment as well as implementation of therapy and therapeutic exercise, physiatrists can help maximize functional independence for children with this group of disorders. Pharmacological treatment includes GABA-agonists including baclofen and benzodiazepines, alpha-2 adrenergic agonists, l-dopa and dopaminergic agents, and dantrolene. Intrathecal baclofen may be used in patients refractory to these medications. In addition, physicians may utilize botulinum toxin, phenol, or surgical interventions such as selective dorsal rhizotomy or tendon lengthening. Pharmacological treatment must be used in conjunction with appropriate adaptive equipment in order to maximize therapeutic benefit. Focus on function in an attempt to increase independence is targeted to improve the child's quality of life. We present a framework and rationale to the management of the functional consequences of the paediatric neurotransmitter diseases.</abstract><cop>Dordrecht</cop><pub>Dordrecht : Springer Netherlands</pub><pmid>19449166</pmid><doi>10.1007/s10545-009-1190-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0141-8955 |
| ispartof | Journal of inherited metabolic disease, 2009-06, Vol.32 (3), p.381-386 |
| issn | 0141-8955 1573-2665 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67282998 |
| source | MEDLINE; SpringerNature Journals; Access via Wiley Online Library |
| subjects | Biochemistry Biological and medical sciences Brain Diseases, Metabolic, Inborn - etiology Brain Diseases, Metabolic, Inborn - therapy Child General aspects Human Genetics Humans Internal Medicine Medical genetics Medical sciences Medicine Medicine & Public Health Metabolic Diseases Models, Biological Motor Activity - physiology Muscle Tonus - physiology Neurotransmitter Agents - deficiency Neurotransmitter Agents - physiology Pediatrics Physical and Rehabilitation Medicine - methods Posture - physiology Symposium on Neurotransmitter Disorders |
| title | Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T14%3A22%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increasing%20physical%20function%20through%20physiatric%20intervention%20for%20children%20with%20paediatric%20neurotransmitter%20disorders&rft.jtitle=Journal%20of%20inherited%20metabolic%20disease&rft.au=Evans,%20S&rft.date=2009-06&rft.volume=32&rft.issue=3&rft.spage=381&rft.epage=386&rft.pages=381-386&rft.issn=0141-8955&rft.eissn=1573-2665&rft.coden=JIMDDP&rft_id=info:doi/10.1007/s10545-009-1190-0&rft_dat=%3Cproquest_cross%3E1747905231%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218867654&rft_id=info:pmid/19449166&rfr_iscdi=true |